Origenis
Business Services · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Am Klopferspitz 19a, Planegg, Bavaria, 8...Phone Number
+49 8978016760Website
www.origenis.deRevenue
$7.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Origenis
Origenis GmbH specializes in curing diseases through the development of novel small molecule drugs, particularly in areas where no existing treatments have been discovered. The company utilizes an AI-driven technology platform to create synergistic drug pipelines that focus on highly selective protein kinase and protease inhibitors. Their innovative BRAINstorm and EYEdeal technologies enable drugs to effectively cross the blood-brain barrier and reach target organs in the eye. With over 20 years of experience in modernizing drug discovery, Origenis aims to address unmet medical needs in various therapeutic areas.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Origenis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Origenis recently announced quarterly report
Check out if Origenis is spiking on competitors!
Funding: Get notified immidiatlly once Origenis has new funding data
Click to see if Origenis had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Origenis
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Origenis, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Origenis launches new products
Check if Origenis has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Origenis
Find 3 more new buyers
Company Profile Activity
Activity Insights
Origenis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Origenis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Origenis.
Origenis Tech Stack
A closer look at the technologies used by Origenis
Origenis News & Media
Neuron23™ Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 /PRNewswire/ -- Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced its launch backed by a combined $113.5 million Series...Origenis GmbH Announces Research Collaboration with U.S. Cancer Center
MARTINSRIED, Germany--(BUSINESS WIRE)--Origenis, a privately-held German AI drug discovery and development company, to collaborate with Memorial Sloan Kettering to target glioblastoma.Origenis GmbH Announces Global License and Collaboration Agreement with Expansion Therapeutics for Novel Therapies Targeting RNA-mediated Diseases
MARTINSRIED, Germany--(BUSINESS WIRE)--Origenis announced today it has entered into a global license and collaboration agreement with Expansion Therapeutics to research and discover small molecule compounds targeting RNA-mediated diseases. As part of the agreement, the companies will initiate a lead optimization program which leverages the Origenis artificial intelligence (AI) discovery platform to identify drug development candidates for Expansion’s portfolio of RNA-targeted small molecule medOrigenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer
MARTINSRIED, Germany--(BUSINESS WIRE)--Origenis GmbH, a German biotech company specializing in the discovery and development of highly selective small molecule kinase inhibitors for CNS disorders, today announced the appointment of Dr. Peter Seufer-Wasserthal as Chief Business Officer. Dr. Seufer-Wasserthal brings 25 years experience in technology oriented business development to the company. Prior to joining Origenis, he served as Vice President Business Development at Intrexon Corporation (NY
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Origenis
Sign Up For FreeTo access detailed company insights
Origenis GmbH specializes in curing diseases through the development of novel small molecule drugs, particularly in areas where no existing treatments have been discovered. The company utilizes an AI-driven technology platform to create synergistic drug pipelines that focus on highly selective protein kinase and protease inhibitors. Their innovativ... Read More
